It is therefore vital that additional biomarkers of BE responses be identified in order to more effectively identify those EGFR wild-type patients who are most likely to benefit from BE treatment in order to guide appropriate patient treatment strategies. The gene discussed is EGFR; the disease is Barrett esophagus.